Physcion-8-O-β-d-glucoside interferes with the nuclear factor-κB pathway and downregulates P-glycoprotein expression to reduce paclitaxel resistance in ovarian cancer cells
Authors:
Open Access
- 18 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (4) , 545-552
Abstract
This study assessed whether physcion-8-O-beta-D-monoglucoside (PG) sensitises paclitaxel (PTX)-resistant ovarian cancer cells and explored the underlying mechanism. Ovarian cancer SK-OV-3 cells were used to establish PTX-resistant SK-OV-3 (SK-OV-3/PTX) cells. The Cell Counting Kit-8 assay and crystal violet staining were used to determine cell viability. P-glycoprotein (P-gp) and nuclear factor (NF)-κB expression and cell distributions were detected using immunofluorescence. Cell apoptosis and protein expression changes were detected using flow cytometry and western blotting, respectively. Effect of PG in vivo was evaluated using a xenograft tumour model. P-gp expression in tumour tissues was detected using immunohistochemical staining. PG (1–10 μm) did not significantly affect SK-OV-3/PTX cell proliferation but significantly downregulated P-gp expression. PG pretreatment (1–10 μm) enhanced PTX cytotoxicity. PG treatment decreased the quantity of phosphorylated-NF-κB p65 in SK-OV-3/PTX cell total proteins and upregulated IKBα expression. Simultaneously, it decreased NF-κB p65 levels in nuclear proteins. PG (1–10 μm) inhibited NF-κB p65 entry into the nucleus. PTX plus PG significantly inhibited SK-OV-3/PTX xenograft tumour growth. PG (1–10 μm) reduced P-gp expression in transplanted tumour tissue. PG can enhance the sensitivity of PTX-resistant ovarian cancer cells SK-OV-3/PTX to PTX, and this effect is related to inhibiting NF-κB from entering the nucleus and down-regulating the expression of P-gp protein.Keywords
Funding Information
- Shandong Province Medical and Health Technology Development Project (2017WSA10016)
This publication has 32 references indexed in Scilit:
- Intact Soluble P-Glycoprotein is Secreted by Sinonasal Epithelial CellsAmerican Journal of Rhinology & Allergy, 2016
- TPGS modified reduced bovine serum albumin nanoparticles as a lipophilic anticancer drug carrier for overcoming multidrug resistanceJournal of Materials Chemistry B, 2016
- NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancerOncogene, 2016
- Different regulation of P-glycoprotein function between Caco-2 and Caki-1 cells by ezrin, radixin and moesin proteinsJournal of Pharmacy and Pharmacology, 2016
- P-glycoprotein in autoimmune rheumatic diseasesAutoimmunity Reviews, 2015
- Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cellsAnti-Cancer Drugs, 2014
- A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitroCancer Letters, 2013
- Activity–lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragmentsBioorganic & Medicinal Chemistry Letters, 2013
- The Correlation Between Bioactive Components ofFallopia multifloraRoot and Environmental FactorsThe American Journal of Chinese Medicine, 2010
- Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathwayPsychoneuroendocrinology, 2009